The world is experiencing the worst international outbreak of infectious disease (Covid‐19) for over a century. The global economy is suffering a downturn greater than was seen in the 2008 financial crash and the spectres of depression and mass death haunts many nations. Across the world, the political response to the crisis has varied, and still does, from denial to initiating huge technical and financial support programmes and mass communication operations. In all this, there are some positives with the immense sacrifices of health care professionals, public sector workers and volunteers to the forefront. The contributions from the biotechnology sciences community have also been significant.

In the not too distant past, it would have seemed unbelievable that, as the significance of the new infection became apparent, scientists in China would be able to sequence the complete viral genome within hours and make this freely available online to researchers across the globe; this enables new, rapid detection systems for both the virus and antiviral antibodies to be developed in short order. Simultaneously, laboratories turned their attention to the challenge of developing vaccines that, whilst they may not be available to confine the initial outbreaks, may help minimise the effects of the subsequent rounds of infection that will appear as present societal constraints are relaxed and could protect against future outbreaks of the SARS‐CoV‐2 virus infection. Other laboratories are focusing on identifying possible therapeutics to reduce the impact of infection.

Of course, in the end the R&D has to be applied to actual manufacture, which is where the response, inevitably, may slow down. The practicality of the various novel vaccine platforms has to be validated through safety and efficacy testing. For vaccines, this normally can take many years, but pharmaceutical licencing authorities are seeking to fast track their approval processes, whilst minimising the risk of unintended consequences. At the end of this chain sits manufacture. Are there suitable facilities available and are there enough technical workers trained in Pharmaceutical Good manufacturing practice to make sufficient quantities of several novel vaccines to facilitate early safety and efficacy studies and, eventually, deliver the required quantities of product to the right quality and timescale? At least in this last respect Big Pharma is showing its willingness to contribute.

When we emerge from this crisis there will, justifiably, be praise and thanks for those who contributed and sacrificed so much for their fellow citizens. Politicians will, no doubt, be self congratulatory but will they look at their prior actions, or inactions, that may have made the battle so much more difficult? China has taken bold societal actions that seem to have been effective. South Korea is one country which seems to have been well prepared and effective in its actions especially in respect of compliance with WHO pandemic advice, undoubtedly because of its previous experience with the earlier SARS epidemic. Elsewhere, governmental responses have varied with some seemingly avoiding compliance with WHO guidelines on pandemics and others following this advice. This uneven approach will hinder our full understanding of the pandemic and the benefit, or otherwise, of the various responses. The advice of scientific experts has, perhaps belatedly, been taken on board in many countries, as witness the new phenomenon of *social distancing*.

Scientists and engineers, working hard to provide accurate and proper information in scientific journals and sites, have long advised governments of the need to insure against future disasters by paying the necessary insurance policy premiums. Not only does this include fundamental research on infectious diseases, public health capabilities, raising public awareness, stockpiling of specialist equipment and protective clothing and emergency manufacturing capability, but also the broader environmental issues that threaten populations globally. We can but hope that the present crisis makes our leaders extend their political view to broader horizons.
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